<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://www.kinexpharma.com/wp-content/plugins/google-sitemap-generator/sitemap.xsl"?><!-- generator="wordpress/3.3.1" -->
<!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.2.6" -->
<!-- generated-on="February 17, 2012 4:39 pm" -->
<!-- Debug: Total comment count: 0 -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://www.kinexpharma.com/</loc>
		<lastmod>2010-11-04T19:26:29+00:00</lastmod>
		<changefreq>daily</changefreq>
		<priority>1.0</priority>
	</url>
<!-- Debug: Start Postings -->
	<url>
		<loc>http://www.kinexpharma.com/drug-pipeline</loc>
		<lastmod>2012-02-17T16:39:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/drug-pipeline/orascovery</loc>
		<lastmod>2012-02-17T15:14:14+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 655: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-acquires-rights-for-technology-and-products-from-hanmi-pharmaceuticals-in-united-states-and-european-union-territories</loc>
		<lastmod>2012-01-03T15:01:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 636: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kx2-391-has-entered-into-phase-1b-clinical-trial</loc>
		<lastmod>2012-01-03T15:00:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 649: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-presents-at-annual-aasld-meeting</loc>
		<lastmod>2011-12-12T15:30:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/clinical-trials</loc>
		<lastmod>2011-12-09T14:31:40+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/careers/current-openings</loc>
		<lastmod>2011-12-06T18:45:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/drug-pipeline/immunology</loc>
		<lastmod>2011-08-22T19:20:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/drug-pipeline/kx02</loc>
		<lastmod>2011-08-22T19:19:18+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/investors</loc>
		<lastmod>2011-08-22T19:17:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/our-company/board-of-directors</loc>
		<lastmod>2011-08-22T19:02:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/our-company/management</loc>
		<lastmod>2011-06-28T17:54:05+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 600: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-appoints-mr-flint-besecker-to-the-board-of-directors</loc>
		<lastmod>2011-06-23T12:51:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 604: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-closes-5m-round-of-financing</loc>
		<lastmod>2011-06-23T12:51:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/careers/current-openings/senior-research-scientist-medicinal-chemistry</loc>
		<lastmod>2011-06-09T12:58:25+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 593: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/the-oishei-foundation-makes-investment-in-kinex-pharmaceuticals</loc>
		<lastmod>2011-06-03T14:38:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 550: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/hanmi-pharmaceuticals-to-acquire-the-rights-for-a-promising-phase-ii-anti-cancer-src-kinasepretubulin-dual-inhibitor-from-kinex-pharmaceuticals-in-selected-asian-territories</loc>
		<lastmod>2011-05-20T02:17:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 573: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/mr-chuck-lannon-vice-chairman-of-kinex-pharmaceuticals-has-been-elected-to-the-board-of-directors-at-the-hauptman-woodward-medical-research-institute</loc>
		<lastmod>2011-05-20T02:17:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 559: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/the-board-of-directors-of-kinex-pharmaceuticals-appoints-dr-allen-barnett-as-president-emeritus-and-dr-johnson-lau-as-chief-executive-officer</loc>
		<lastmod>2011-05-20T02:16:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 582: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/the-board-of-directors-of-kinex-pharmaceuticals-appoints-dr-david-hangauer-as-chief-scientific-officer</loc>
		<lastmod>2011-05-20T02:16:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/our-company/ceo-message</loc>
		<lastmod>2011-05-09T19:45:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/contact-us</loc>
		<lastmod>2011-04-08T19:48:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/careers/current-openings/senior-clinical-study-manager</loc>
		<lastmod>2011-03-08T17:10:35+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/careers/current-openings/medical-writer</loc>
		<lastmod>2011-03-08T16:57:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/careers</loc>
		<lastmod>2011-03-08T15:23:12+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/drug-pipeline/kx01</loc>
		<lastmod>2011-03-08T15:10:29+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/our-company</loc>
		<lastmod>2011-03-08T14:31:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 469: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-receives-therapeutic-discovery-grant</loc>
		<lastmod>2010-12-08T15:19:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 128: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-ceo-to-present-at-national-venture-capital-conference</loc>
		<lastmod>2010-12-06T14:48:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.kinexpharma.com/contact-us/accommodations</loc>
		<lastmod>2010-11-23T13:53:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 231: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/from-lab-bench-to-board-room-ub-chemists-powerful-approach-to-anti-cancer-compounds-makes-the-leap</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 224: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-honored-by-the-university-at-buffalo</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 228: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/faculty-research-at-ub-pays-off-in-patents-and-start-ups</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 51: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/post-2006</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 222: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-closes-on-seed-round-financing</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 226: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-achieves-significant-rd-milestones</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 54: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/post-2005</loc>
		<lastmod>2010-11-08T14:41:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 218: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-executes-exclusive-license-with-suny-at-buffalo</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 213: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-receives-investment-from-bdf</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 215: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-recognized-by-the-university-at-buffal</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 220: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-elects-new-member-to-board-of-directors</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 211: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-acquires-exclusive-license-to-develop-drugs-for-hearing-loss</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 209: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-selects-lead-drug-candidate-for-clinical-development-in-oncology</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 199: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-selects-kxo1-as-a-clinical-candidate-for-oncology</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 201: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/us-patent-issued</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 203: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-receives-grant-from-the-center-for-advanced-technology-in-biomedical-and-bioengineering</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 205: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-closes-on-additional-equity-investments</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 207: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-receives-investment-from-the-niagara-region-venture-fund</loc>
		<lastmod>2010-11-08T14:41:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 189: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-annual-meeting-to-be-held-on-april-24</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 197: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-relocates</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 168: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/insyte-consulting-honors-kinex-pharmaceuticals</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 163: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kx2-391-allowed-to-proceed-to-phase-1-trials</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 166: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-files-ind-for-kx2-391-with-the-us-food-and-drug-administration</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 184: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-presents-at-international-cancer-meeting</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 159: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/discovery-of-kx2-391-presented-at-international-conference</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 187: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-co-founder-receives-multiple-honors</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 191: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/two-us-patents-issued</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 193: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-receives-grant-awards</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 195: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-closes-most-successful-round-of-fund-raising</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 161: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-founder-presentation-distinguished</loc>
		<lastmod>2010-11-08T14:41:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 120: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/pharmaceutical-industry-veteran-is-appointed-cmo-at-kinex-pharmaceuticals</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 155: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/start-of-clinical-trial-for-kx2-391</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 138: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/david-hsia-ph-d-co-founder-of-watson-pharmaceuticals-joins-kinex-board-of-directors</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 122: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-completes-round-of-financing</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 124: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-phase-1-clinical-data-selected-as-best-of-asco</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 126: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-receives-phase-2-sbir-award-from-the-national-cancer-institut</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 152: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-awarded-us-patent</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 149: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-co-founder-appointed-to-nyba-board</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 147: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-raises-more-than-3-million-in-equity-financing</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 144: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-presents-at-2008-aacr-meeting</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 142: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/hangauer-named-inventor-of-the-year</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 140: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/pre-clinical-development-efforts-are-focused-on-a-new-compound-for-brain-tumors</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 157: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kx2-391-enters-phase-1-clinical-trials-for-oncology</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 136: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-completes-another-successful-round-of-financing</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 134: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-board-member-killed-in-tragic-plane-accident</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 132: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kxo2-will-be-developed-to-treat-brain-cancer</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 129: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/charles-e-lannon-elected-to-kinex-board-of-directors</loc>
		<lastmod>2010-11-08T14:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 38: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-named-to-science-coalition-list</loc>
		<lastmod>2010-11-08T14:41:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 42: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-technology-highlighted-at-american-chemical-society-symposium</loc>
		<lastmod>2010-11-08T14:41:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 45: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/charles-e-lannon-appointed-as-vice-chairman-of-the-board-at-kinex-pharmaceuticals</loc>
		<lastmod>2010-11-08T14:41:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 48: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-pharmaceuticals-initiates-a-phase-2-clinical-trial-of-kx2-391-in-patients-with-prostate-cancer</loc>
		<lastmod>2010-11-08T14:41:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1: Comments: 0 of 0 = 0 points -->
	<url>
		<loc>http://www.kinexpharma.com/kinex-presents-at-aacr</loc>
		<lastmod>2010-11-08T14:41:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: End Postings -->
<!-- Debug: Start Custom Pages -->
<!-- Debug: End Custom Pages -->
<!-- Debug: Start additional URLs -->
<!-- Debug: End additional URLs -->
</urlset>